Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.31
GSK's Cash to Debt is ranked lower than
54% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. GSK: 0.31 )
GSK' s 10-Year Cash to Debt Range
Min: 0.02   Max: 0.85
Current: 0.31

0.02
0.85
Equity to Asset 0.17
GSK's Equity to Asset is ranked lower than
58% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. GSK: 0.17 )
GSK' s 10-Year Equity to Asset Range
Min: 0.05   Max: 0.37
Current: 0.17

0.05
0.37
Interest Coverage 9.68
GSK's Interest Coverage is ranked higher than
53% of the 460 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 88.77 vs. GSK: 9.68 )
GSK' s 10-Year Interest Coverage Range
Min: 0.81   Max: 28.06
Current: 9.68

0.81
28.06
F-Score: 6
Z-Score: 2.53
M-Score: -2.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 26.52
GSK's Operating margin (%) is ranked higher than
94% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.34 vs. GSK: 26.52 )
GSK' s 10-Year Operating margin (%) Range
Min: 1.68   Max: 36.94
Current: 26.52

1.68
36.94
Net-margin (%) 20.51
GSK's Net-margin (%) is ranked higher than
92% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.48 vs. GSK: 20.51 )
GSK' s 10-Year Net-margin (%) Range
Min: 5.76   Max: 23.94
Current: 20.51

5.76
23.94
ROE (%) 77.69
GSK's ROE (%) is ranked higher than
100% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. GSK: 77.69 )
GSK' s 10-Year ROE (%) Range
Min: 18.39   Max: 253.19
Current: 77.69

18.39
253.19
ROA (%) 12.92
GSK's ROA (%) is ranked higher than
96% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.94 vs. GSK: 12.92 )
GSK' s 10-Year ROA (%) Range
Min: 3.87   Max: 27.12
Current: 12.92

3.87
27.12
ROC (Joel Greenblatt) (%) 79.22
GSK's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 732 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.50 vs. GSK: 79.22 )
GSK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.07   Max: 93.68
Current: 79.22

5.07
93.68
Revenue Growth (%) -0.90
GSK's Revenue Growth (%) is ranked higher than
58% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. GSK: -0.90 )
GSK' s 10-Year Revenue Growth (%) Range
Min: -1.5   Max: 91
Current: -0.9

-1.5
91
EBITDA Growth (%) 17.30
GSK's EBITDA Growth (%) is ranked higher than
81% of the 507 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. GSK: 17.30 )
GSK' s 10-Year EBITDA Growth (%) Range
Min: -11.8   Max: 85.9
Current: 17.3

-11.8
85.9
EPS Growth (%) 51.40
GSK's EPS Growth (%) is ranked higher than
94% of the 510 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. GSK: 51.40 )
GSK' s 10-Year EPS Growth (%) Range
Min: -30.2   Max: 93.9
Current: 51.4

-30.2
93.9
» GSK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

GSK Guru Trades in Q2 2013

Diamond Hill Capital 9,561 sh (New)
John Rogers 39,366 sh (+460.45%)
Steven Cohen 12,804 sh (+9.92%)
Manning & Napier Advisors, Inc 395,224 sh (+4.12%)
Ken Fisher 11,148,275 sh (+0.74%)
PRIMECAP Management 10,125,855 sh (+0.24%)
Murray Stahl 22,673 sh (unchged)
Jeff Auxier 112,870 sh (unchged)
John Hussman 23,500 sh (unchged)
Joel Greenblatt Sold Out
Tweedy Browne 151,090 sh (-0.12%)
Dodge & Cox 61,935,959 sh (-1.09%)
Warren Buffett 1,476,021 sh (-2.28%)
NWQ Managers 211,800 sh (-2.71%)
Charles Brandes 1,931,938 sh (-3.19%)
Jim Simons 1,357,500 sh (-16.17%)
Vanguard Health Care Fund 1,611,181 sh (-26.11%)
Jean-Marie Eveillard 1 sh (-100%)
» More
Q3 2013

GSK Guru Trades in Q3 2013

John Rogers 136,344 sh (+246.35%)
Jim Simons 3,891,300 sh (+186.65%)
Diamond Hill Capital 11,561 sh (+20.92%)
Murray Stahl 23,723 sh (+4.63%)
Manning & Napier Advisors, Inc 400,161 sh (+1.25%)
NWQ Managers 211,800 sh (unchged)
Jean-Marie Eveillard 1 sh (unchged)
John Hussman 23,500 sh (unchged)
Tweedy Browne 151,030 sh (-0.04%)
Jeff Auxier 112,720 sh (-0.13%)
Ken Fisher 11,119,081 sh (-0.26%)
PRIMECAP Management 10,078,655 sh (-0.47%)
Dodge & Cox 61,290,600 sh (-1.04%)
Charles Brandes 1,896,714 sh (-1.82%)
Vanguard Health Care Fund 1,438,781 sh (-10.7%)
Steven Cohen 8,963 sh (-30%)
Warren Buffett 345,819 sh (-76.57%)
» More
Q4 2013

GSK Guru Trades in Q4 2013

Joel Greenblatt 83,452 sh (New)
Francis Chou 18,000 sh (New)
John Hussman 423,500 sh (+1702.13%)
John Rogers 421,201 sh (+208.93%)
Jim Simons 6,425,000 sh (+65.11%)
Charles Brandes 2,145,461 sh (+13.11%)
Ken Fisher 11,126,274 sh (+0.06%)
Jean-Marie Eveillard 1 sh (unchged)
Diamond Hill Capital 11,561 sh (unchged)
Murray Stahl 23,723 sh (unchged)
Steven Cohen Sold Out
Warren Buffett Sold Out
Jeff Auxier 112,170 sh (-0.49%)
Tweedy Browne 150,184 sh (-0.56%)
PRIMECAP Management 9,998,877 sh (-0.79%)
NWQ Managers 209,325 sh (-1.17%)
Dodge & Cox 60,479,650 sh (-1.32%)
Manning & Napier Advisors, Inc 383,698 sh (-4.11%)
Vanguard Health Care Fund 644,881 sh (-55.18%)
» More
Q1 2014

GSK Guru Trades in Q1 2014

Ken Fisher 11,214,364 sh (+0.79%)
Manning & Napier Advisors, Inc 329,053 sh (-14.24%)
» More
» Details

Insider Trades

Latest Guru Trades with GSK

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-12-31 Add 1702.13%1.51%$49.31 - $53.68 $ 55.146%423500
Charles Brandes 2013-12-31 Add 13.11%0.16%$49.31 - $53.68 $ 55.146%2145461
Vanguard Health Care Fund 2013-12-31 Reduce -55.18%0.14%$49.31 - $53.68 $ 55.146%644881
Joel Greenblatt 2013-12-31 New Buy0.11%$49.31 - $53.68 $ 55.146%83452
Warren Buffett 2013-12-31 Sold Out 0.02%$49.31 - $53.68 $ 55.146%0
Warren Buffett 2013-09-30 Reduce -76.57%0.06%$50.27 - $52.96 $ 55.147%345819
Joel Greenblatt 2013-06-30 Sold Out 0.16%$46.79 - $53.59 $ 55.149%0
Vanguard Health Care Fund 2013-06-30 Reduce -26.11%0.1%$46.79 - $53.59 $ 55.149%1611181
Jean-Marie Eveillard 2013-06-30 Reduce -100%0.05%$46.79 - $53.59 $ 55.149%1
John Hussman 2013-03-31 Reduce -95.51%0.57%$43.47 - $46.91 $ 55.1423%23500
Vanguard Health Care Fund 2013-03-31 Reduce -20.49%0.07%$43.47 - $46.91 $ 55.1423%2180381
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about GlaxoSmithKline PLC

Top Yields in Berkshire Hathaway’s Portfolio
According to GuruFocus research, Warren Buffett’s firm Berkshire Hathaway Inc. (BRK.A, BRK.B) gains its highest dividends from GlaxoSmithKline PLC (GSK), ConocoPhillips (COP), General Electric Co. (GE) and Procter & Gamble Co. (PG). Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 14.80
GSK's P/E(ttm) is ranked higher than
87% of the 528 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.60 vs. GSK: 14.80 )
GSK' s 10-Year P/E(ttm) Range
Min: 10.16   Max: 40.41
Current: 14.8

10.16
40.41
P/B 11.41
GSK's P/B is ranked lower than
71% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.84 vs. GSK: 11.41 )
GSK' s 10-Year P/B Range
Min: 5.48   Max: 14.06
Current: 11.41

5.48
14.06
P/S 3.04
GSK's P/S is ranked higher than
55% of the 722 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.99 vs. GSK: 3.04 )
GSK' s 10-Year P/S Range
Min: 1.94   Max: 4.9
Current: 3.04

1.94
4.9
PFCF 14.54
GSK's PFCF is ranked higher than
88% of the 330 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.86 vs. GSK: 14.54 )
GSK' s 10-Year PFCF Range
Min: 8.21   Max: 41.33
Current: 14.54

8.21
41.33
EV-to-EBIT 13.13
GSK's EV-to-EBIT is ranked higher than
80% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.45 vs. GSK: 13.13 )
GSK' s 10-Year EV-to-EBIT Range
Min: 7.6   Max: 239.5
Current: 13.13

7.6
239.5
PEG 6.17
GSK's PEG is ranked higher than
52% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. GSK: 6.17 )
GSK' s 10-Year PEG Range
Min: 0.23   Max: 99.36
Current: 6.17

0.23
99.36
Shiller P/E 17.68
GSK's Shiller P/E is ranked higher than
81% of the 362 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.59 vs. GSK: 17.68 )
GSK' s 10-Year Shiller P/E Range
Min: 10.82   Max: 21.72
Current: 17.68

10.82
21.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.48
GSK's Dividend Yield is ranked higher than
98% of the 419 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.38 vs. GSK: 4.48 )
GSK' s 10-Year Dividend Yield Range
Min: 2.72   Max: 5.69
Current: 4.48

2.72
5.69
Dividend Payout 0.70
GSK's Dividend Payout is ranked lower than
62% of the 367 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. GSK: 0.70 )
GSK' s 10-Year Dividend Payout Range
Min: 0.51   Max: 4.05
Current: 0.7

0.51
4.05
Dividend growth (3y) 6.40
GSK's Dividend growth (3y) is ranked higher than
80% of the 236 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. GSK: 6.40 )
GSK' s 10-Year Dividend growth (3y) Range
Min: -12.6   Max: 20.8
Current: 6.4

-12.6
20.8
Yield on cost (5-Year) 6.17
GSK's Yield on cost (5-Year) is ranked higher than
97% of the 430 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.42 vs. GSK: 6.17 )
GSK' s 10-Year Yield on cost (5-Year) Range
Min: 3.73   Max: 7.8
Current: 6.17

3.73
7.8
Share Buyback Rate 1.40
GSK's Share Buyback Rate is ranked higher than
92% of the 483 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.70 vs. GSK: 1.40 )
GSK' s 10-Year Share Buyback Rate Range
Min: 51.8   Max: -20
Current: 1.4

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.53
GSK's Price/DCF (Projected) is ranked higher than
73% of the 346 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. GSK: 1.53 )
GSK' s 10-Year Price/DCF (Projected) Range
Min: 0.94   Max: 4.41
Current: 1.53

0.94
4.41
Price/Median PS Value 1.04
GSK's Price/Median PS Value is ranked higher than
66% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.10 vs. GSK: 1.04 )
GSK' s 10-Year Price/Median PS Value Range
Min: 0.77   Max: 2.57
Current: 1.04

0.77
2.57
Earnings Yield (Greenblatt) 7.60
GSK's Earnings Yield (Greenblatt) is ranked higher than
82% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. GSK: 7.60 )
GSK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 13.1
Current: 7.6

0.4
13.1
Forward Rate of Return (Yacktman) 4.95
GSK's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 532 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. GSK: 4.95 )
GSK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.2   Max: 72
Current: 4.95

2.2
72

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:JNJ, PFE, RHHBY, NVS, ABT » details
Traded in other countries:GSK.UK, GLAXF.USA, GS7A.Germany, GS7.Germany
GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-virals including HIV, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, vaccines and dermatologicals. The Company operates in two industry segments: Pharmaceuticals and Consumer Healthcare. The Company's pharmaceutical products include treatments for asthma, HIV/AIDS, malaria, depression, migraine, diabetes, heart failure, digestive conditions and cancer. The Company markets over 25 vaccines worldwide to prevent potentially life-threatening or crippling illnesses such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza and bacterial meningitis. The Company produces medicines that treat six major disease areas - asthma, virus control, infections, mental health, diabetes and digestive conditions. In addition, it is developing new treatments for cancer. The Company's portfolio comprises three main categories: OTC medicines, Oral healthcare and Nutritional healthcare. OTC medicines- alli is the first licensed weight loss medicine to be available without a prescription, launched in the USA in 2007. Oral healthcare- Aquafresh, a range of toothpastes, toothbrushes and mouthwashes; Sensodyne, a range of toothpastes and toothbrushes, including Pronamel to protect from acid erosion; Biotene; Polident, PoliGrip and Corega, the denture care cleansers and adhesives; and Other brands include Odol, Macleans and Dr Best. Nutritional healthcare- Lucozade is a range of energy and sports drinks; Horlicks, a range of milk-based malted food and chocolate drinks; and Ribena, a blackcurrant juice-based drink. The Company has operations in USA, Europe, Asia Pacific, Japan and Canada.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide